CN115381874A - Traditional Chinese medicine composition and granules for treating chicken non-infectious diarrhea and preparation method - Google Patents
Traditional Chinese medicine composition and granules for treating chicken non-infectious diarrhea and preparation method Download PDFInfo
- Publication number
- CN115381874A CN115381874A CN202210808804.9A CN202210808804A CN115381874A CN 115381874 A CN115381874 A CN 115381874A CN 202210808804 A CN202210808804 A CN 202210808804A CN 115381874 A CN115381874 A CN 115381874A
- Authority
- CN
- China
- Prior art keywords
- parts
- polysaccharide
- traditional chinese
- chinese medicine
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 208000001848 dysentery Diseases 0.000 title claims abstract description 42
- 206010012742 Diarrhoea infectious Diseases 0.000 title claims abstract description 41
- 241000287828 Gallus gallus Species 0.000 title claims abstract description 37
- 239000008187 granular material Substances 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 150000004676 glycans Chemical class 0.000 claims abstract description 77
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 77
- 239000005017 polysaccharide Substances 0.000 claims abstract description 77
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 31
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 22
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 20
- 241000675108 Citrus tangerina Species 0.000 claims abstract description 19
- HRYLQFBHBWLLLL-UHFFFAOYSA-N (+)-costunolide Natural products C1CC(C)=CCCC(C)=CC2OC(=O)C(=C)C21 HRYLQFBHBWLLLL-UHFFFAOYSA-N 0.000 claims abstract description 18
- CUGKULNFZMNVQI-UHFFFAOYSA-N Costunolid I Natural products CC1=CCC=C(/C)CCC2C(C1)OC(=O)C2=C CUGKULNFZMNVQI-UHFFFAOYSA-N 0.000 claims abstract description 18
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 18
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 18
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 18
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 18
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 18
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 18
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 18
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 18
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 18
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 18
- WKSUCCVMYJRMFR-UHFFFAOYSA-N Dehydrocostus lactone Natural products C12OC(=O)C(=C)C2CCC(=C)C2(C)C1(C)C(=C)CC2 WKSUCCVMYJRMFR-UHFFFAOYSA-N 0.000 claims abstract description 18
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 18
- HRYLQFBHBWLLLL-AHNJNIBGSA-N costunolide Chemical compound C1CC(/C)=C/CC\C(C)=C\[C@H]2OC(=O)C(=C)[C@@H]21 HRYLQFBHBWLLLL-AHNJNIBGSA-N 0.000 claims abstract description 18
- MMTZAJNKISZWFG-UHFFFAOYSA-N costunolide Natural products CC1CCC2C(CC(=C/C=C1)C)OC(=O)C2=C MMTZAJNKISZWFG-UHFFFAOYSA-N 0.000 claims abstract description 18
- NETSQGRTUNRXEO-XUXIUFHCSA-N dehydrocostus lactone Chemical compound C([C@H]1C(=C)C(=O)O[C@@H]11)CC(=C)[C@H]2[C@@H]1C(=C)CC2 NETSQGRTUNRXEO-XUXIUFHCSA-N 0.000 claims abstract description 18
- 229930003935 flavonoid Natural products 0.000 claims abstract description 18
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 18
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 18
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 claims abstract description 17
- 229960004191 artemisinin Drugs 0.000 claims abstract description 17
- 229930101531 artemisinin Natural products 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 15
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940043353 maltol Drugs 0.000 claims abstract description 14
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 10
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 10
- 229940010454 licorice Drugs 0.000 claims abstract description 10
- 241001061264 Astragalus Species 0.000 claims abstract description 9
- 210000004233 talus Anatomy 0.000 claims abstract description 9
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000001263 FEMA 3042 Substances 0.000 claims abstract description 7
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims abstract description 7
- 229920002258 tannic acid Polymers 0.000 claims abstract description 7
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims abstract description 7
- 229940033123 tannic acid Drugs 0.000 claims abstract description 7
- 235000015523 tannic acid Nutrition 0.000 claims abstract description 7
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 143
- 238000000605 extraction Methods 0.000 claims description 48
- 239000000243 solution Substances 0.000 claims description 47
- 239000000706 filtrate Substances 0.000 claims description 46
- 238000005303 weighing Methods 0.000 claims description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 33
- 235000013330 chicken meat Nutrition 0.000 claims description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000843 powder Substances 0.000 claims description 31
- 238000001035 drying Methods 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 22
- 229930003944 flavone Natural products 0.000 claims description 22
- 150000002212 flavone derivatives Chemical class 0.000 claims description 22
- 235000011949 flavones Nutrition 0.000 claims description 22
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 22
- 241000125175 Angelica Species 0.000 claims description 21
- 238000001914 filtration Methods 0.000 claims description 20
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 19
- 238000001704 evaporation Methods 0.000 claims description 18
- 239000000284 extract Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 15
- 238000007873 sieving Methods 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 238000002137 ultrasound extraction Methods 0.000 claims description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 12
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 239000003208 petroleum Substances 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 239000002994 raw material Substances 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 10
- 229920001353 Dextrin Polymers 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 235000019425 dextrin Nutrition 0.000 claims description 9
- 230000008020 evaporation Effects 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 9
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 238000000643 oven drying Methods 0.000 claims description 9
- 238000000967 suction filtration Methods 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 229920001864 tannin Polymers 0.000 claims description 8
- 235000018553 tannin Nutrition 0.000 claims description 8
- 239000001648 tannin Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 235000001405 Artemisia annua Nutrition 0.000 claims description 6
- 240000000011 Artemisia annua Species 0.000 claims description 6
- 241000045403 Astragalus propinquus Species 0.000 claims description 6
- 241000756943 Codonopsis Species 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000011344 liquid material Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 6
- 238000001291 vacuum drying Methods 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 241000382455 Angelica sinensis Species 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 238000003828 vacuum filtration Methods 0.000 claims description 4
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 229920000742 Cotton Polymers 0.000 claims description 3
- 240000007049 Juglans regia Species 0.000 claims description 3
- 235000009496 Juglans regia Nutrition 0.000 claims description 3
- 108010059820 Polygalacturonase Proteins 0.000 claims description 3
- 244000197580 Poria cocos Species 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 244000272264 Saussurea lappa Species 0.000 claims description 3
- 235000006784 Saussurea lappa Nutrition 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 230000015556 catabolic process Effects 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 239000012045 crude solution Substances 0.000 claims description 3
- 239000013078 crystal Substances 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 108010093305 exopolygalacturonase Proteins 0.000 claims description 3
- 238000013401 experimental design Methods 0.000 claims description 3
- 238000001125 extrusion Methods 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000010903 husk Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000009210 therapy by ultrasound Methods 0.000 claims description 3
- 235000020234 walnut Nutrition 0.000 claims description 3
- 238000005238 degreasing Methods 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 241001063953 Angelica shikokiana Species 0.000 claims 2
- 241000576755 Sclerotia Species 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 abstract description 37
- 238000004519 manufacturing process Methods 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 37
- 235000019441 ethanol Nutrition 0.000 description 36
- 235000013601 eggs Nutrition 0.000 description 25
- 210000000952 spleen Anatomy 0.000 description 14
- 241001092040 Crataegus Species 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000011084 recovery Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 5
- 229930194248 Licoflavone Natural products 0.000 description 4
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 4
- 206010033557 Palpitations Diseases 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000017448 oviposition Effects 0.000 description 4
- 244000045947 parasite Species 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940083618 sodium nitroprusside Drugs 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000282461 Canis lupus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 241000222684 Grifola Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000242678 Schistosoma Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 229960002521 artenimol Drugs 0.000 description 1
- BJDCWCLMFKKGEE-ISOSDAIHSA-N artenimol Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-ISOSDAIHSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004913 chyme Anatomy 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 229920003045 dextran sodium sulfate Polymers 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229930016266 dihydroartemisinin Natural products 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000036750 egg laying performance Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention belongs to the technical field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating chicken non-infectious diarrhea, granules and a preparation method thereof, wherein the traditional Chinese medicine composition for treating the chicken non-infectious diarrhea consists of 10 parts of angelica polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of a mixture of costunolide and dehydrocostuslactone, 5 parts of green tangerine peel tannic acid, 5 parts of maltol, 5 parts of hawthorn total flavonoids, 5 parts of artemisinin, 5 parts of poria polysaccharide, 5 parts of licorice flavonoids, 6 parts of astragalus polysaccharide and 8 parts of dried orange peel flavonoids according to the mass parts. Clinical and pharmacodynamic tests prove that the traditional Chinese medicine compound granules for treating the non-infectious diarrhea of the caged chicken can recover the egg yield of the sick laying hens within 5 days, and the mortality rate is only 4 percent. The compound granules can also be used as a health-care medicine for promoting the weight gain of laying hens and improving the egg yield of the laying hens, is a high-efficiency treatment health-care medicine for synergistically treating diarrhea of the laying hens and increasing the production capacity of the laying hens, and has high economic value and innovation.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating non-infectious diarrhea of cage-bred chickens and a preparation method thereof.
Background
In recent years, in the cage-raised chicken industry, non-infectious diarrhea has become one of the common diseases, and due to the slow onset of the diseases, the high incidence rate, the long course of disease, the obvious reduction of the laying rate of the laying hens and the difficult treatment, the production enthusiasm of the majority of farmers is seriously influenced. The disease is caused by a plurality of reasons, mainly including high chicken flock density, high chicken coop temperature, high humidity and poor ventilation; the feed quality is poor, the mixture ratio is improper, and the feeding management level is low; large, repeated and long-term use of antibiotics and chemicals in the course of ordinary prevention and treatment of diseases; these all can lead to cold-heat dampness stagnating in the stomach and intestine, destroying the normal physiological function of the intestinal tract and causing diarrhea.
Because some farmers are not aware of the medicines enough and lack the common sense of rational medication, in the process of preventing and treating diseases usually, a large amount of repeated and long-term use of antibiotics and chemicals leads to the reduction of the detoxification capability of liver and kidney, the disturbance of the digestion function of organisms, the unbalance of normal flora in intestinal tracts and serious diarrhea. The onset symptoms are mental collapse, loose and disorganized feathers, inappetence or abstinence, black and green feces which are watery diarrhea-like. The change of the autopsy is that the intestinal mucosa falls off, the intestinal wall becomes thin, the intestinal canal is loose and has no elasticity, and the intestines are filled with water sample chyme. The prevention and treatment method is based on the principles of promoting blood circulation by removing blood stasis, regulating qi-flowing for relieving diarrhea, invigorating spleen and promoting appetite; meanwhile, the normal ecological flora in the intestinal tract is recovered, and the balance of osmotic pressure is adjusted.
In recent years, with the market demand, the breeding scale is continuously expanded, the cage layer industry is in a gradual development stage, and the cage layer not only enriches a plurality of farmers, but also provides high-quality livestock and poultry food for people. However, in the actual breeding process, the laying hens often suffer from diarrhea caused by factors such as feed, environment, medicines and the like in the growth process, the diarrhea is not infected and is not caused by virus and bacterial infection, but still has negative influence on the economic benefit of farmers, the yield and the quality of eggs are greatly reduced, and if the diarrhea of the non-infected laying hens is not prevented or treated, the large-scale death phenomenon of laying hen groups is easily caused, so that the farmers need to pay attention to the diarrhea symptoms of the laying hens in the breeding process of cage-breeding the laying hens, and the early discovery and the early treatment are realized as soon as possible. The non-infectious caged laying hens are mainly treated by drugs such as antibiotics and the like due to diarrhea, non-viruses, bacteria or parasites and other pathogenic microorganisms, and the treatment scheme mainly comprises an adjusting mode, such as adjusting a feed formula, improving the environment of a feeding house, reducing the use of antibiotics and the like. The traditional Chinese medicine has natural advantages for the diarrhea caused by the non-pathogenic microorganisms and has good recuperation efficacy, but most of the traditional Chinese medicine prescription for treating the diarrhea is prepared by matching and processing raw materials, and has the following defects: 1) Contains a large amount of ineffective components, and is easy to cause medicine residue. 2) Some ineffective components have mutually opposite properties, so that the curative effect of the prescription is easily reduced. 3) The raw material without extraction has many impurities and poor absorption. Therefore, there is a need to design a new Chinese medicinal composition.
Through the above analysis, the problems and defects of the prior art are as follows:
the traditional Chinese medicine formula for treating diarrhea of the laying hens at present contains a large amount of ineffective components, so that medicine residues are easily caused; some ineffective components have mutually opposite attributes, so that the curative effect of the prescription is easily reduced; the raw material without extraction has many impurities and poor absorption.
The defects of improving the environment and nutrition are as follows: the effect is slow, needs to be slowly adjusted, and often has the phenomenon that the symptom cannot be corrected.
The defects of the traditional Chinese medicine formula at present are as follows: 1) Contains a large amount of ineffective components, and is easy to cause medicine residue. 2) Some ineffective components have mutually conflicting properties, and the curative effect of the formula is easily reduced. 3) The raw material without extraction has many impurities and poor absorption.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a traditional Chinese medicine composition for treating non-infectious diarrhea of cage-raised chickens and a preparation method thereof, and particularly relates to traditional Chinese medicine extract composition compound particles for treating non-infectious diarrhea of cage-raised chickens and a preparation method thereof.
The traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken is prepared from 10 parts by mass of angelica polysaccharide, 15 parts by mass of codonopsis pilosula polysaccharide, 5 parts by mass of costunolide and dehydrocostuslactone mixture, 5 parts by mass of green tangerine peel tannic acid, 5 parts by mass of maltol, 5 parts by mass of hawthorn total flavonoids, 5 parts by mass of artemisinin, 5 parts by mass of poria polysaccharide and 5 parts by mass of licoflavone.
Further, the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken also comprises 6 parts of astragalus polysaccharide and 8 parts of dried orange peel flavone, and the optimal dosage of the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken is 1.5g/kg.
Another object of the present invention is to provide a method for preparing a Chinese medicinal composition for treating non-infectious diarrhea in caged chicken, which comprises the following steps:
step one, respectively weighing 10 parts of angelica polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of costunolide, 5 parts of dehydrocostuslactone, 5 parts of green tangerine peel tannin, 5 parts of maltol, 5 parts of hawthorn total flavone, 5 parts of artemisinin, 5 parts of poria polysaccharide and 5 parts of licorice flavone, pouring the mixture into a stirring cylinder, adding a small amount of warm water, and fully stirring to form a viscous mixture A;
step two, taking 30 parts of starch and pretreating the starch, and drying the starch after the pretreatment is finished; after drying, carrying out heat treatment on the starch and then cooling the starch again to obtain the required white dextrin;
dissolving 8 parts of sucrose in a small amount of warm water, and fully stirring to form a sucrose solution;
pouring the obtained white dextrin and sucrose solution into a stirring cylinder, and fully stirring and uniformly mixing the white dextrin and the sucrose solution with the mixture A; adjusting the pH value of the solution by using 50% sodium hydroxide solution, adjusting the pH value of the solution to 7.2, and standing for 1 hour for later use to form a mixed material B;
and step five, pouring the mixed material B into particle preparation equipment for extrusion molding, wherein the particle size is 2-3 mm, drying the prepared particles after molding, and finally sterilizing and packaging.
Further, the angelica polysaccharide extraction method comprises the following steps:
(1) Pretreatment of raw materials: crushing 8g of angelica slices, and sieving the angelica slices with a 40-mesh sieve; heat-treating the raw materials with 80% ethanol solution at 70 deg.C for 2 times, each for 1 hr, removing small molecular substances such as monosaccharide, oligosaccharide, pigment and polypeptide, and inactivating enzyme to prevent degradation of polysaccharide by enzyme; filtering, and vacuum drying to obtain radix Angelicae sinensis powder.
(2) And (3) extracting polysaccharide: extracting radix Angelicae sinensis powder with hot water, centrifuging at 3000r/min for 20min, mixing supernatants, and adjusting pH to 4.5; centrifuging at 3000r/min for 20min, and concentrating the supernatant; adding 4 times of 95% ethanol, standing, filtering, precipitating, sequentially washing with anhydrous ethanol, acetone and diethyl ether, vacuum drying, and extracting with water to obtain crude polysaccharide.
Further, the codonopsis pilosula polysaccharide extraction method comprises the following steps:
(1) Pretreatment: accurately weighing 18g of codonopsis pilosula; adding 4mL of distilled water per g of codonopsis pilosula, and then adding 8mL of petroleum ether per g of codonopsis pilosula for extraction and degreasing; after 1h, separating petroleum ether from the codonopsis pilosula, adding 6mL of 80% ethanol for each gram of codonopsis pilosula, soaking, and putting in a refrigerator at 4 ℃ overnight;
(2) Alcohol removal: removing ethanol by suction filtration, and adding a certain amount of distilled water for extraction;
(3) Ultrasonic extraction: extracting for a certain time at a certain temperature and power according to an experimental design and a certain feed-liquid ratio;
(4) Collecting filtrate: separating the filtrate and the filter residue obtained in the first extraction by suction filtration, and collecting the filtrate; adding a certain amount of water into the filter residue, and extracting again under the same condition; carrying out suction filtration on the extracting solution for the second time, collecting filtrate, and combining the filtrate with the filtrate for the first time;
(5) And (3) concentrating under reduced pressure: concentrating the filtrate to 1/7-1/8 of the combined filtrate;
(6) Alcohol precipitation: adding ethanol into the cooled concentrated solution, adjusting the concentrated solution until the ethanol content reaches 65%, and placing in a refrigerator at 4 deg.C overnight; taking the supernatant, washing the precipitate twice with 65% ethanol of the same concentration, and combining the filtrates; removing ethanol in the filtrate by rotary evaporation, and finally volatilizing the ethanol remained in the filtrate on a water bath;
(7) Drying and weighing: drying in a drying oven at 60 deg.C to constant weight, and weighing.
Further, the method for extracting costunolide and dehydrocostus lactone from costus root comprises the following steps: weighing 5.00g of radix aucklandiae powder, placing in a special round bottom flask, adding anhydrous ethanol, performing microwave treatment at microwave power of 400W for 3min, and filtering to obtain filtrate as extractive solution; rotary evaporating, oven drying at 40 deg.C to obtain mixed extract of costunolide and dehydrocostus lactone, and weighing.
Further, the preparation method of the green tangerine peel tannin extracting solution comprises the following steps: weighing 5-6 g of walnut green husk dry powder in a triangular flask, adding ethanol/water solution with a certain volume fraction according to a certain liquid-material ratio, and placing in an ultrasonic cleaner to enable the water surface of the ultrasonic cleaner to be flush with the liquid level in the triangular flask; setting ultrasonic extraction time and temperature, starting the ultrasonic cleaning machine for a certain time, stopping the ultrasonic cleaning machine, and taking out the ultrasonic cleaning machine; centrifuging at 3000r/min for 30min, vacuum filtering, collecting filtrate, concentrating with rotary evaporator, collecting extract, and weighing.
The maltol extraction method comprises the following steps: weighing 5g of malt, crushing and screening by a 60-mesh sieve; according to the following steps of 1: adding ethanol with volume fraction of 70% into the mixture at a ratio of 20g/mL, and performing ultrasonic-assisted secondary extraction for 30min; centrifuging at 2500r/min for 4min, rotary evaporating, oven drying at 40 deg.C to obtain polyphenol extract, and weighing.
Further, the extraction method of the hawthorn total flavonoids comprises the following steps: by using a compound enzymolysis-assisted ultrasonic extraction method, 5g of hawthorn is treated by 3% of cellulase and 4% of pectinase, the treatment pH is 6.0, the enzymolysis temperature is 60 ℃, the enzymolysis time is 1.5h, the ethanol concentration is 70%, and the material-liquid ratio is 1: extracting 40g/mL with ultrasound at 40 deg.C for 30min to obtain total flavone extract 85.5mg/g.
The method for extracting the sweet wormwood herb comprises the following steps: weighing a proper amount of sweet wormwood powder 5g, adding petroleum ether, sealing, placing in an ultrasonic crusher for ultrasonic action, and filtering with a filter membrane; adding equal amount of petroleum ether into the filter residue, performing ultrasonic treatment again, and combining the filtrates; centrifuging at 2500r/min for 10min, collecting supernatant, evaporating to dryness under reduced pressure, dissolving with 95% ethanol to obtain ethanol solution of artemisinin, and concentrating by evaporation to obtain crystal.
Further, the extraction method of the grifola polysaccharide comprises the following steps: cutting dried Poria sclerotium into pieces, weighing 5g, pulverizing with pulverizer, and sieving with 60 mesh sieve; taking a proper amount of powder, adding 80% ethanol solution, reflux-extracting at 70 deg.C for 2h, repeating the extraction step for 2 times, taking the filter residue, air drying, and weighing to obtain defatted Poria powder.
The extraction method of the licorice flavonoids comprises the following steps: weighing 7g of liquorice and pretreating the overground part of the liquorice;
wherein, the pretreatment of the overground part of the liquorice comprises the following steps: collecting aerial parts of Glycyrrhrizae radix of the same batch, folding into small segments, oven drying at 60 deg.C, pulverizing, and sieving with 80 mesh sieve; weighing 5g of sieved powder to be used in a round-bottom flask, adding an extraction solvent, heating and extracting, carrying out vacuum filtration, taking filtrate, and carrying out evaporation concentration.
Further, the preparation method of the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken also comprises the steps of extracting astragalus polysaccharide and extracting dried orange peel flavone;
the extraction method of the astragalus polysaccharide comprises the following steps: drying and crushing astragalus membranaceus decoction pieces, sieving by a 40-mesh sieve, taking 10g of astragalus membranaceus powder, adding pure water according to the designed liquid-material ratio, and performing ultrasonic extraction according to the designed corresponding extraction temperature and extraction time; filtering with gauze or absorbent cotton, concentrating to 20mL, adding 3 times volume of anhydrous ethanol, standing for several hours, and standing in refrigerator overnight for precipitation; centrifuging in a centrifuge, and drying to obtain crude polysaccharide.
The extraction method of the tangerine peel flavone comprises the following steps: drying pericarpium Citri Tangerinae in a thermostat at 60 deg.C, cooling in a glass drier, pulverizing, drying, and sieving with 0.45mm sieve; weighing pericarpium Citri Tangerinae powder 3g, adding ethanol with certain concentration, extracting at different temperatures and material-solvent ratio for a period of time, vacuum filtering to obtain flavone crude solution, and concentrating by evaporation.
The invention also aims to provide a traditional Chinese medicine compound granule prepared by using the traditional Chinese medicine composition, wherein the traditional Chinese medicine compound granule comprises the traditional Chinese medicine composition for treating non-infectious diarrhea of caged chickens, and the traditional Chinese medicine composition comprises 10 parts by mass of angelica polysaccharide, 15 parts by mass of codonopsis pilosula polysaccharide, 5 parts by mass of costunolide and dehydrocostuslactone mixture, 5 parts by mass of green tangerine peel tannic acid, 5 parts by mass of maltol, 5 parts by mass of hawthorn total flavonoids, 5 parts by mass of artemisinin, 5 parts by mass of poria polysaccharide and 5 parts by mass of licoflavone.
In combination with the above technical solutions and the technical problems to be solved, please analyze the advantages and positive effects of the technical solutions to be protected in the present invention from the following aspects:
first, aiming at the technical problems existing in the prior art and the difficulty in solving the problems, the technical problems to be solved by the technical scheme of the present invention are closely combined with results, data and the like in the research and development process, and some creative technical effects are brought after the problems are solved. The specific description is as follows:
the invention provides a traditional Chinese medicine extract formula, which is prepared from angelica polysaccharide, codonopsis pilosula polysaccharide, costunolide, dehydrocostuslactone mixture, green tangerine peel tannin, maltol, hawthorn total flavone, artemisinin, poria polysaccharide and licorice flavone through processing, and the traditional Chinese medicine compound granule for treating non-infectious diarrhea of cage-raised chickens is prepared.
Secondly, considering the technical scheme as a whole or from the perspective of products, the technical effect and advantages of the technical scheme to be protected by the invention are specifically described as follows:
the compound granules provided by the invention can also be used as a health-care medicine for promoting the weight increase of laying hens and improving the egg yield of the laying hens, is a high-efficiency treatment health-care medicine for synergistically treating diarrhea of the laying hens and increasing the production capacity of the laying hens, and has high economic value and innovation.
Third, as inventive supplementary proof of the claims of the present invention, there are several important aspects as follows:
(1) The expected income and commercial value after the technical scheme of the invention is converted are as follows:
after the technical scheme is converted, the death rate of the laying hens is obviously reduced, the egg yield is obviously improved, and the pure profit can be increased by about 1000 yuan after every 1000 laying hens use the compound treatment health-care granules through preliminary calculation. Has the advantages of extremely high commercial value,
(2) The technical scheme of the invention fills the technical blank in the industry at home and abroad:
the technology develops the traditional Chinese medicine compound granule in the aspect of treating the diarrhea of the laying hens, the traditional Chinese medicine compound granule is mainly prepared from the extracts of the effective components of the Chinese herbal medicines, the preparation is not simple, the compound granule has the effects of increasing egg yield, increasing weight and the like, the preparation is not simple, the traditional Chinese patent medicine in China at present only is prepared from the Chinese herbal medicines and has no health-care effect.
(3) The technical scheme of the invention solves the technical problem that people are eagerly to solve but can not be successfully solved all the time:
the traditional Chinese medicine compound granule can treat all the non-infectious diarrhea of the cage-reared laying hens, has quick response and good curative effect, and solves the technical blank that the disease has no accurate treatment method and medicament.
Drawings
In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings needed to be used in the embodiments of the present invention will be briefly described below, and it is obvious that the drawings described below are only some embodiments of the present invention, and it is obvious for those skilled in the art that other drawings can be obtained according to the drawings without creative efforts.
FIG. 1 is a flow chart of a preparation method of a traditional Chinese medicine composition for treating non-infectious diarrhea of caged chicken provided by the embodiment of the invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Aiming at the problems in the prior art, the invention provides a traditional Chinese medicine composition for treating non-infectious diarrhea of caged chickens and a preparation method thereof, and the invention is described in detail with reference to the attached drawings.
1. Illustrative embodiments are explained. This section is an illustrative example developed to explain the claims in order to enable those skilled in the art to fully understand how to implement the present invention.
Example 1
The traditional Chinese medicine composition for treating non-infectious diarrhea of caged chickens, provided by the embodiment of the invention, comprises, by mass, 10 parts of angelica sinensis polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of costunolide and dehydrocostuslactone mixture, 5 parts of green tangerine peel tannic acid, 5 parts of maltol, 5 parts of hawthorn total flavonoids, 5 parts of artemisinin, 5 parts of poria polysaccharide and 5 parts of licorice flavonoids.
The medicine provided by the embodiment of the invention has the following effects and effective components for treating diarrhea of laying hens:
chinese angelica: enriching the blood; promoting blood circulation; regulating menstruation and relieving pain; moisten dryness and smooth intestines. The main symptoms are blood deficiency; irregular menstruation; amenorrhea; dysmenorrhea; the symptoms are accumulated; (ii) metrorrhagia and metrostaxis; abdominal pain due to deficiency-cold; flaccidity and paralysis; numbness of the skin; intestinal dryness and difficult defecation; severe dysentery with diarrhea; carbuncle, cellulitis, sore and ulcer; injury from falling.
The effective components for treating diarrhea: angelica polysaccharide.
Codonopsis pilosula: has effects in invigorating spleen, replenishing qi, invigorating spleen, benefiting lung, resisting cancer, lowering blood pressure, resisting anoxia, resisting aging, enhancing immunity, improving activity of superoxide dismutase, enhancing free radical scavenging ability, regulating gastrointestinal motility, resisting ulcer, inhibiting gastric acid secretion, and reducing pepsin activity. It is suitable for treating spleen and lung deficiency, short breath, palpitation, anorexia, loose stool, ulcer, anemia, asthma, cough, internal heat, and thirst.
The effective components for treating diarrhea: and (4) codonopsis pilosula polysaccharide.
Costustoot: move qi, alleviate pain, invigorate spleen and promote digestion. The effective components for treating diarrhea: costunolide and dehydrocostuslactone.
Green tangerine peel: has the effects of soothing liver, relieving qi stagnation, and removing food stagnation. The effective components for treating diarrhea: green tangerine peel tannic acid.
Hawthorn, malt and sweet wormwood: governing qi stagnation, descending food, breaking accumulation and diaphragmatic qi. The effective components for treating diarrhea: fructus crataegi total flavone, maltol, and artemisinin.
Poria cocos (wolf) wolf: can be used for treating edema, oliguria, phlegm and fluid retention, dizziness, palpitation, spleen deficiency, anorexia, loose stool, diarrhea, uneasiness, palpitation, and insomnia.
The effective components for treating diarrhea: a polysaccharide of Poria.
Licorice root: it can be used for treating heart-qi deficiency, palpitation, intermittent pulse, spleen and stomach qi deficiency, listlessness, and asthenia. The medicines are combined together and have the effects of moistening dryness and lubricating intestines.
The effective components for treating diarrhea: licoflavone.
Pharmacological analysis:
angelica polysaccharide: anti-inflammatory, angelicae polysaccharide is aimed at various inflammatory treatments. Chondrocyte apoptosis plays an important role in the development of Osteoarthritis (OA). Xuc finds that angelica polysaccharide has a protective effect on Sodium Nitroprusside (SNP) induced chondrocyte apoptosis, and discusses the mechanism of the angelica polysaccharide. The angelica polysaccharide can enhance autophagy by activating an extracellular regulatory protein kinase pathway, inhibit SNP-induced chondrocyte apoptosis and become a potential substitute for OA treatment. Studies such as CHENG F and the like show that the angelica polysaccharide can reduce the activity of colon tissue myeloperoxidase and regulate the expression of proinflammatory cytokines and related proteins, thereby inhibiting the dextran sodium sulfate from inducing the experimental colitis of mice.
The function of the codonopsis pilosula polysaccharide is as follows:
the Codonopsis Pilosula Polysaccharide (CPPS) can effectively enhance organ indexes of thymus, spleen and the like and carbon clearance rate of immunosuppressive mice caused by Cyclophosphamide (CTX), and can simultaneously effectively relieve the inhibition of the immune functions of the mice caused by CTX. The effect of selenized codonopsis pilosula polysaccharide (sCPPS) on the immune performance of immunosuppressive mice caused by CTX is researched on the basis of lindane and the like, and the result shows that the codonopsis pilosula polysaccharide can enhance the immune activity of the immunosuppressive mice, so that the spleen index and the thymus index of the mice are obviously improved, and the sCPPS effect is superior to that of the CPPS. The polysaccharide can promote development, structural improvement and lymphocyte proliferation of mouse spleen, thereby enhancing immunity. The selenization modification can further improve the immunocompetence of the codonopsis pilosula polysaccharide, and has a certain dose dependence relationship, and the higher the dose is, the stronger the activity is.
The codonopsis pilosula polysaccharide can be used as a component medicine of an immunopotentiator under the conditions of single medicine and combined medicine.
The codonopsis pilosula polysaccharide can increase the number and activity of lymphocytes and enable the lymphocytes around the artery of the spleen of a mouse to be dense.
The function of costunolide and dehydrocostuslactone is as follows:
DHC shows good bacteriostatic activity. Such as DHC, has certain inhibiting effect on the growth of helicobacter pylori
The green tangerine peel tannin has the effects of bacteriostasis, diarrhea stopping, oxidation resistance, immunity improvement and the like.
Action of maltols: : has the effects of resisting oxidation, inhibiting bacteria, diminishing inflammation and the like.
The effect of the hawthorn total flavonoids is as follows: : has blood pressure lowering, digestive tract dysfunction regulating, and spleen function improving effects. Can promote the secretion of digestive enzymes and reduce the blood sugar level of diabetes. Has antibacterial, antiinflammatory, immunity regulating, and antioxidant effects.
The artemisinin has the following effects:
the effective substances in the artemisinin, such as dihydroartemisinin, artemether and the like can play a good role in killing plasmodium;
the anti-tumor effect can induce the apoptosis of tumor cells, inhibit the angiogenesis of the tumor cells and enhance the sensitivity of radiotherapy and chemotherapy, thereby achieving the anti-tumor effect;
the artemisinin can play an antagonistic role on inflammatory factors such as interleukin 12, tumor necrosis factor alpha and the like, so that the anti-inflammatory effect is achieved.
The parasite killing composition can be used for treating parasites such as schistosome, and has good parasite killing effect.
Polysaccharide of Poria cocos: has effects of relieving swelling, promoting urination, nourishing heart, tranquilizing mind, and invigorating spleen and stomach.
The extraction process of each component provided by the embodiment of the invention is as follows:
1. process for extracting angelica polysaccharide
Pretreating raw materials, namely crushing 8g of angelica slices and sieving the crushed angelica slices with a 40-mesh sieve. Referring to AOAC method, the raw material is heat-treated with 80% volume fraction ethanol solution at 70 deg.C for 2 times (2 × 1 h) to remove small molecular substances such as monosaccharide, oligosaccharide, pigment and polypeptide, and simultaneously inactivate enzyme to prevent degradation of polysaccharide by enzyme. Filtering, and vacuum drying to obtain radix Angelicae sinensis powder.
Extracting radix Angelicae sinensis powder pretreated by polysaccharide extraction process with hot water, centrifuging (3000 r/min, 20 min), mixing supernatants, adjusting pH to 4.5, centrifuging (3000 r/min, 20 min), concentrating the supernatant, adding 4 times of 95% ethanol, standing, filtering, precipitating, sequentially washing with anhydrous ethanol, acetone, and diethyl ether, vacuum drying, and extracting crude polysaccharide with water.
2. Process for extracting codonopsis pilosula polysaccharide
Pretreatment: 18g of codonopsis pilosula is accurately weighed. Adding distilled water 4mL per gram of radix Codonopsis, adding petroleum ether 8mL per gram of radix Codonopsis, extracting and defatting for 1 hr, separating petroleum ether from radix Codonopsis, adding 80% ethanol 6mL per gram of radix Codonopsis, soaking, and placing in refrigerator at 4 deg.C overnight. Alcohol removal: removing ethanol by suction filtration, and adding a certain amount of distilled water for extraction. Ultrasonic extraction: extracting for a certain time at a certain temperature and power according to an experimental design and a certain feed-liquid ratio. Collecting filtrate: and separating the filtrate and the filter residue obtained in the first extraction by suction filtration, and collecting the filtrate. Adding a certain amount of water into the filter residue, and extracting again under the same condition. And carrying out suction filtration on the second extracting solution, collecting filtrate, and combining the filtrate with the first filtrate. And (3) concentrating under reduced pressure: and concentrating the filtrate to 1/7-1/8 of the combined filtrate. Alcohol precipitation: adding ethanol into the cooled concentrated solution, adjusting the concentrated solution until the ethanol content reaches 65%, and placing in a refrigerator at 4 deg.C overnight. Taking supernatant, washing the precipitate twice with 65% ethanol, and combining filtrates. Removing ethanol in the filtrate by rotary evaporation, and finally volatilizing the ethanol remained in the filtrate on a water bath kettle. Drying and weighing: drying in a drying oven at 60 deg.C to constant weight, and weighing.
3. Costunolide and dehydrocostus lactone in Costus root
Precisely weighing 5.00g of radix aucklandiae powder, placing into a special round bottom for burning, adding anhydrous ethanol into a bottle, performing microwave treatment at a microwave power of 400W for 3min, and filtering to obtain filtrate as extractive solution. Rotary evaporating, oven drying at 40 deg.C to obtain mixed extract of costunolide and dehydrocostus lactone, and weighing.
4. Green tangerine peel tannin extract
Accurately weighing 5-6 g of walnut green husk dry powder in a triangular flask, adding ethanol/water solution with a certain volume fraction according to a certain liquid-material ratio, placing the mixture in an ultrasonic cleaner, enabling the water surface in the ultrasonic cleaner to be level with the liquid surface in the triangular flask, setting ultrasonic extraction time and temperature, starting the ultrasonic cleaner for a certain time, stopping the ultrasonic cleaner, taking out the ultrasonic cleaner, centrifuging the ultrasonic cleaner for 30min at 3000r/min, carrying out vacuum filtration, collecting filtrate, concentrating the filtrate by using a rotary evaporator, collecting extracted products, and weighing.
5. Extraction of maltol
Accurately weighing 5g of malt, crushing, screening (60 meshes), and performing the following steps of 1:20 Adding 70% ethanol at a material-to-liquid ratio (g/mL), ultrasonic-assisted extracting for 30min (secondary extraction), centrifuging at 2500r/min for 4min, rotary evaporating, oven drying at 40 deg.C to obtain polyphenol extract, and weighing.
6. Extraction method of hawthorn total flavonoids
The compound enzymolysis auxiliary ultrasonic extraction method comprises the following steps: treating 5g of hawthorn with 3% of cellulase and 4% of pectinase, wherein the treatment pH is 6.0, the enzymolysis temperature is 60 ℃, the enzymolysis time is 1.5h, the ethanol concentration is 70%, and the material-liquid ratio is 1:40 (g/mL) and ultrasonic extraction at 40 ℃ for 30min, wherein the extraction amount of the total flavone can reach 85.5mg/g.
7. Method for extracting sweet wormwood herb
Accurately weighing appropriate amount of herba Artemisiae Annuae powder 5g, adding petroleum ether, sealing, placing in an ultrasonic crusher for ultrasonic action, and filtering with filter membrane. Adding petroleum ether into the residue, performing ultrasonic treatment again, mixing filtrates, centrifuging (2500 r/min,10 min), collecting supernatant, evaporating under reduced pressure, dissolving with 95% ethanol to obtain ethanol solution of artemisinin, and concentrating by evaporation to obtain crystal.
8. Extraction process of poria polysaccharide
Cutting dried Poria sclerotium into pieces, weighing 5g, pulverizing with a pulverizer, sieving with 60 mesh sieve, collecting appropriate amount of powder, adding 80% ethanol solution, reflux-extracting at 70 deg.C for 2 hr, repeating above steps for 2 times, collecting residue, air drying, and weighing to obtain defatted Poria powder.
9. Process for extracting licoflavone
Weighing 7g of liquorice to fully utilize the overground part of the liquorice, improving the yield of total flavonoids, reducing test errors and needing to pretreat the overground part of the liquorice. The specific operation is as follows: collecting aerial parts of Glycyrrhrizae radix of the same batch, folding into small segments, oven drying at 60 deg.C, pulverizing, and sieving with 80 mesh sieve. Weighing 5g of sieved powder to be used in a round-bottom flask, adding an extraction solvent, heating and extracting for a certain time, carrying out vacuum filtration, taking filtrate, and carrying out evaporation concentration.
As shown in fig. 1, the preparation method of the traditional Chinese medicine granule provided by the embodiment of the invention comprises the following steps:
s101, 10 parts of angelica polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of costunolide, dehydrocostuslactone, 5 parts of green tangerine peel tannin, 5 parts of maltol, 5 parts of hawthorn total flavone, 5 parts of artemisinin, 5 parts of poria polysaccharide and 5 parts of licorice flavone are poured into a stirring tank, and a small amount of warm water is added for fully stirring to form a viscous mixture A;
s102, taking 30 parts of starch, then pretreating the starch, drying the starch after the pretreatment is finished, and performing heat treatment and cooling on the starch after the drying is finished so as to obtain the required white dextrin;
s103, dissolving 8 parts of sucrose in a small amount of warm water, and fully stirring to form a sucrose solution;
s104, pouring the obtained white dextrin and sucrose solution into a stirring cylinder, and fully stirring and uniformly mixing the white dextrin and the sucrose solution with the mixture A; regulating the pH value of the solution by using 50% sodium hydroxide solution, regulating the pH value of the solution to 7.2, and standing for 1h for later use to form a mixed material B; pouring the mixed material B into particle preparation equipment for extrusion forming, wherein the particle size is 2-3 mm, drying the prepared particles after forming, and finally sterilizing and packaging.
Example 2
The traditional Chinese medicine composition for treating non-infectious diarrhea of cage-raised chickens, provided by the embodiment of the invention, further comprises:
1. astragalus polysaccharides (6 parts)
The efficacy is as follows: has effects in invigorating qi, consolidating superficial resistance, promoting diuresis, relieving edema, expelling pus, and promoting granulation.
Extraction process
Drying and crushing astragalus membranaceus decoction pieces, sieving by a 40-mesh sieve, taking 10g of astragalus membranaceus powder, adding pure water according to the designed liquid-material ratio, carrying out ultrasonic extraction at the designed corresponding extraction temperature and extraction time, filtering by gauze or absorbent cotton, concentrating to 20mL, adding 3 times of volume of absolute ethyl alcohol, standing for several hours, standing overnight in a refrigerator for precipitation, centrifuging in a centrifuge, and finally drying to obtain crude polysaccharide.
2. Dried orange peel flavone (8 parts)
The efficacy is as follows: regulating qi and strengthening spleen
The extraction process comprises the following steps: dried orange peel is dried in a thermostat at 60 ℃, and then cooled, crushed, dried and sieved by a 0.45mm sieve in a glass drier. Weighing pericarpium Citri Tangerinae powder 3g, adding ethanol with certain concentration, extracting at different temperatures and material-solvent ratio (material-liquid ratio) for a certain time, vacuum filtering to obtain flavone crude solution, and concentrating by evaporation.
The original formula is as follows: firstly, the original formula is a mixture prepared from traditional Chinese medicine raw materials, and impurities are more and are not always effective components. The second two new drugs have obvious advantages in egg yield recovery and health recovery time (see table 1).
TABLE 1 comparison of the efficacy of the original formulation with the existing formulation
Compared with the existing formula (traditional Chinese medicine extract compound granules), the original formula has obvious disadvantages in the aspects of egg yield and weight increment after the laying hens recover health.
TABLE 2 comparison of egg yield and body weight of laying hens after their health recovery
Two medicines are added, the effective components are extracted, and after the dosage of the effective components is changed, the main effect is as follows: 1) The recovery time is shortened, and the health can be restored in 5 days. 2) The recovery time of the egg yield is shortened, and the egg yield is improved compared with that of normal laying hens due to the effects of qi tonifying, superficial resistance strengthening and the like of the astragalus, which has a health-care effect. The egg yield of the original formula cannot be restored to the original health level. 3) The existing compound granules have short recovery time, the weight loss of the laying hens is little, and primordial qi is not damaged, and the compound granules have the effects of nourishing and health care, so that the recovery and growth speed of the weight is faster than that of the common healthy laying hens and is far faster than that of the prior formula. The weight growth speed of the laying hens before the laying hens are started is positively correlated with the egg yield.
2. Application examples. In order to prove the creativity and the technical value of the technical scheme of the invention, the part is an application example of the technical scheme of the claims to a specific product or related technology.
The technical scheme provided by the embodiment of the invention has been applied to a certain laying hen farm for a plurality of times, and has a very good effect.
(1) In 2020, 300 laying hens in a laying hen farm in a certain city of a certain province produce diarrhea symptoms and do not lay eggs, the compound granules are used for treatment, diarrhea is stopped in two days, laying eggs begin in three days, laying eggs recover in five days, and no death cases exist.
(2) In 2020, in a laying hen farm in a certain city of a certain province, more than 200 laying hens have diarrhea, the diarrhea is preliminarily diagnosed as non-infectious diarrhea, the compound granules are used for treatment, all the diarrhea is cured, and the egg laying amount is obviously improved.
(3) In 2021 year, in some county farm in some city of some province, more than 500 laying hens have symptoms of non-infectious diarrhea, and the compound granule is used for treatment, so that the whole course is cured, and the egg laying amount is obviously improved.
3. Evidence of the relevant effects of the examples. The embodiment of the invention achieves some positive effects in the process of research and development or use, and has great advantages compared with the prior art, and the following contents are described by combining data, diagrams and the like in the test process.
1. Influence of non-treatment on laying hens suffering from non-infectious diarrhea
Analysis shows that the non-infectious diarrhea treatment in short time has great influence on the cage-rearing laying hens, the egg yield is sharply reduced, and the cage-rearing laying hens die. The egg production begins to drop sharply on the first day of the disease, no egg production begins on the third day, and no egg production continues thereafter. Mortality cases began to appear on day 4 of the disease, with mortality reaching a peak on day 6 and all layers in the sample died after day 8 (see table 3).
TABLE 3 disease Change of cage-reared chickens 8 days after infection with non-infectious diarrhea
2. Optimum dosage selection of Chinese medicinal compound granule
The feed is mixed into the Chinese medicinal compound granules according to the dosage of 0.5g, 1.0g, 1.5g, 2.0g, 2.5g and 3.0g of each kg of laying hens, the sick laying hens are fed, the egg laying performance of the laying hens can be recovered by using the dosages of 1.0g/kg, 1.5g/kg and 2.0g/kg, the dosage of 1.5g/kg is optimal, the mortality is low, the egg laying amount is improved compared with the healthy period, and the recovery time is shortest. The use of 1.5g/kg and 2.0g/kg gives the least cases of death and the lowest mortality rate is 4%. But the time for recovering egg laying is short with the dosage of 1.5g/kg, and the dosage is the least. When the dosage exceeds 2.0g/kg, the egg yield of the laying hens tends to decline, and the mortality rate begins to rise. Therefore, the present invention selects 1.5g/kg as the optimal dosage (see Table 4).
TABLE 4 selection of optimal dosage for compound Chinese medicinal granule
3. Curative effect of traditional Chinese medicine compound granules on non-infectious diarrhea of cage-raised laying hens
The non-infectious diarrhea of the cage-bred laying hens is treated by using the traditional Chinese medicine compound granules, the death cases of the laying hens are obviously reduced, the death rate is only 4%, the laying hens begin to recover health in the third day, the egg production begins to recover, the cure rate reaches 100% in the 5 th day, and the egg production recovers to be normal (see table 5).
TABLE 5 therapeutic effect of the Chinese medicinal compound granule
The diarrhea of the non-infectious cage layer is different from bacterial or viral infection, and therapeutic drugs such as antibiotics have no therapeutic effect on the diarrhea, and are generally caused by poor environment of a feeding house, unreasonable dietary structure and abuse of antibiotics in the feeding process. Therefore, the disease is generally relieved by improving the environment of the feeding house, adjusting the dietary structure, reducing resistance and the like. However, the measures have slow effect and high cost, and the pathogeny is difficult to find, thereby causing huge economic loss. Therefore, a traditional Chinese medicine compound granule is developed to treat diarrhea of non-infectious cage-bred laying hens, and the treatment effect is compared and shown in table 6.
TABLE 6 comparison of the curative effects of the compound Chinese medicinal granule and other treatment methods
Analysis shows that after the laying hens are healed by the traditional Chinese medicine compound granules, the egg yield of the laying hens is increased to a certain extent compared with that of healthy laying hens after the traditional Chinese medicine compound granules are continuously taken for a plurality of days, which indicates that the compound granules not only can cure diarrhea of the laying hens, but also can be used as health-care medicines to improve the egg yield (the health is recovered on day 5) (see table 7).
TABLE 7 comparison of egg production of hens not affected (normal) and hens fed with Chinese medicinal compound granule for recovering normal egg production
Meanwhile, experiments show that after the compound granules are taken, the weight recovery and growth speed of the laying hens in the laying and laying periods are higher than those of healthy laying hens, and the compound granules are beneficial to the weight increase of the laying hens and the laying of the laying hens (see table 8).
TABLE 8 weight change of layer chicken
The above description is only for the purpose of illustrating the present invention and the appended claims are not to be construed as limiting the scope of the invention, which is intended to cover all modifications, equivalents and improvements that are within the spirit and scope of the invention as defined by the appended claims.
Claims (10)
1. The traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken is characterized by comprising, by mass, 10 parts of angelica sinensis polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of a mixture of costunolide and dehydrocostuslactone, 5 parts of green tangerine peel tannic acid, 5 parts of maltol, 5 parts of hawthorn total flavonoids, 5 parts of artemisinin, 5 parts of poria polysaccharide and 5 parts of licorice flavonoids.
2. The traditional Chinese medicine composition for treating non-infectious diarrhea of caged chicken of claim 1, wherein the traditional Chinese medicine composition for treating non-infectious diarrhea of caged chicken further comprises 6 parts of astragalus polysaccharides and 8 parts of dried orange peel flavone; the optimal dosage of the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken is 1.5g/kg.
3. A preparation method of a traditional Chinese medicine composition for treating non-infectious diarrhea of a caged chicken, which implements the traditional Chinese medicine composition for treating non-infectious diarrhea of the caged chicken according to any one of claims 1 to 2, wherein the preparation method of the traditional Chinese medicine composition for treating non-infectious diarrhea of the caged chicken comprises the following steps:
step one, respectively weighing 10 parts of angelica polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of costunolide, 5 parts of dehydrocostuslactone, 5 parts of green tangerine peel tannin, 5 parts of maltol, 5 parts of hawthorn total flavone, 5 parts of artemisinin, 5 parts of poria polysaccharide and 5 parts of licorice flavone, pouring the mixture into a stirring tank, adding a small amount of warm water, and fully stirring to form a viscous mixture A;
step two, taking 30 parts of starch and pretreating the starch, drying the starch after the pretreatment is finished, and performing heat treatment and cooling on the starch after the drying is finished so as to obtain the required white dextrin;
step three, taking 8 parts of sucrose, dissolving in a small amount of warm water, and fully stirring to form a sucrose solution;
pouring the obtained white dextrin and sucrose solution into a stirring cylinder, and fully stirring and uniformly mixing the white dextrin and the sucrose solution with the mixture A; adjusting the pH value of the solution by using 50% sodium hydroxide solution, adjusting the pH value of the solution to 7.2, and standing for 1 hour for later use to form a mixed material B;
and step five, pouring the mixed material B into particle preparation equipment for extrusion molding, wherein the particle size is 2-3 mm, drying the prepared particles after molding, and finally sterilizing and packaging.
4. The method of claim 3, wherein the Angelica sinensis polysaccharide is extracted from the group consisting of Angelica sinensis, angelica shikokiana, and Angelica shikokiana.
(1) Pretreatment of raw materials: crushing 8g of angelica slices, and sieving the angelica slices with a 40-mesh sieve; heat-treating the raw materials with 80% ethanol solution at 70 deg.C for 2 times, each for 1 hr, removing small molecular substances such as monosaccharide, oligosaccharide, pigment and polypeptide, and inactivating enzyme to prevent degradation of polysaccharide by enzyme; filtering, and vacuum drying to obtain radix Angelicae sinensis powder;
(2) And (3) extracting polysaccharide: extracting radix Angelicae sinensis powder with hot water, centrifuging at 3000r/min for 20min, mixing supernatants, and adjusting pH to 4.5; centrifuging at 3000r/min for 20min, and concentrating the supernatant; adding 4 times of 95% ethanol, standing, filtering, sequentially washing precipitate with anhydrous ethanol, acetone and diethyl ether, vacuum drying, and extracting crude polysaccharide with water.
5. The preparation method of the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken as set forth in claim 3, wherein the extraction method of the codonopsis pilosula polysaccharide comprises the following steps:
(1) Pretreatment: accurately weighing 18g of codonopsis pilosula; adding 4mL of distilled water per gram of radix codonopsis, and then adding 8mL of petroleum ether per gram of radix codonopsis for extraction and degreasing; after 1h, separating petroleum ether from codonopsis pilosula, adding 6mL of 80% ethanol into each gram of codonopsis pilosula, soaking, and putting in a refrigerator at 4 ℃ overnight;
(2) Alcohol removal: removing ethanol by suction filtration, and adding 5ml of distilled water for extraction;
(3) Ultrasonic extraction: according to the experimental design, the ratio of material to liquid is 1:10 extracting at 40 deg.C and 80w power for a certain time;
(4) Collecting filtrate: separating the filtrate and the filter residue obtained in the first extraction by suction filtration, and collecting the filtrate; adding 4ml of water into the filter residue, and extracting again under the same condition; carrying out suction filtration on the second extracting solution, collecting filtrate, and combining the filtrate with the first filtrate;
(5) And (3) concentrating under reduced pressure: concentrating the filtrate to 1/7-1/8 of the combined filtrate;
(6) Alcohol precipitation: adding ethanol into the cooled concentrated solution, adjusting the concentrated solution until the ethanol content reaches 65%, and placing in a refrigerator at 4 deg.C overnight; taking supernatant, washing the precipitate twice with 65% ethanol of the same concentration, and combining filtrates; removing ethanol in the filtrate by rotary evaporation, and finally volatilizing the ethanol remained in the filtrate on a water bath;
(7) Drying and weighing: drying in a drying oven at 60 deg.C to constant weight, and weighing.
6. The preparation method of the Chinese medicinal composition for treating non-infectious diarrhea in caged chicken as claimed in claim 3, wherein the extraction method of costunolide and dehydrocostuslactone in costus root comprises: weighing 5.00g of radix aucklandiae powder, placing in a special round bottom flask, adding anhydrous ethanol, performing microwave treatment at microwave power of 400W for 3min, and filtering to obtain filtrate as extractive solution; rotary evaporating, oven drying at 40 deg.C to obtain mixed extract of costunolide and dehydrocostus lactone, and weighing.
7. The method of claim 3, wherein the green tangerine peel tannin extract is prepared by the steps of: weighing 5-6 g of walnut green husk dry powder in a triangular flask, adding ethanol/water solution per g of dry powder/5 ml according to the liquid-material ratio of 1; setting ultrasonic extraction time and temperature, starting the ultrasonic cleaning machine for a certain time, stopping the ultrasonic cleaning machine, and taking out the ultrasonic cleaning machine; centrifuging at 3000r/min for 30min, vacuum filtering, collecting filtrate, concentrating with rotary evaporator, collecting extract, and weighing;
the maltol extraction method comprises the following steps: weighing 5g of malt, crushing and screening by 60 meshes; according to the following steps of 1: adding ethanol with volume fraction of 70% into the mixture at a feed-liquid ratio of 20g/mL, and performing ultrasonic-assisted secondary extraction for 30min; centrifuging at 2500r/min for 4min, rotary evaporating, oven drying at 40 deg.C to obtain polyphenol extract, and weighing.
8. The method for preparing the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken as claimed in claim 3, wherein the extraction method of the hawthorn total flavonoids comprises the following steps: by using a compound enzymolysis-assisted ultrasonic extraction method, 5g of hawthorn is treated by 3% of cellulase and 4% of pectinase, the pH value is 6.0, the enzymolysis temperature is 60 ℃, the enzymolysis time is 1.5h, the ethanol concentration is 70%, and the material-liquid ratio is 1: ultrasonic extracting at 40 deg.C for 30min at 40g/mL to obtain total flavone extract 85.5mg/g;
the method for extracting the sweet wormwood herb comprises the following steps: weighing a proper amount of sweet wormwood powder 5g, adding petroleum ether, sealing, placing in an ultrasonic crusher for ultrasonic action, and filtering with a filter membrane; adding equal amount of petroleum ether into the filter residue, performing ultrasonic treatment again, and combining the filtrates; centrifuging at 2500r/min for 10min, collecting supernatant, evaporating to dryness under reduced pressure, dissolving with 95% ethanol to obtain ethanol solution of artemisinin, and concentrating by evaporation to obtain crystal;
the extraction method of the poria polysaccharide comprises the following steps: cutting dried Poria cocos sclerotia into pieces, weighing 5g, crushing by a crusher, and sieving by a 60-mesh sieve; taking a proper amount of powder, adding 80% ethanol solution, reflux-extracting at 70 deg.C for 2h, repeating the extraction step for 2 times, taking the filter residue, air drying, and weighing to obtain defatted Poria powder;
the method for extracting licorice flavonoids comprises the following steps: weighing 7g of liquorice and pretreating the overground part of the liquorice;
wherein, the pretreatment of the overground part of the liquorice comprises the following steps: collecting aerial parts of Glycyrrhrizae radix of the same batch, folding into small segments, oven drying at 60 deg.C, pulverizing, and sieving with 80 mesh sieve; weighing 5g of sieved powder to be used in a round-bottom flask, adding an extraction solvent, heating and extracting, carrying out vacuum filtration, taking filtrate, and carrying out evaporation concentration.
9. The method for preparing the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken as claimed in claim 3, wherein the preparation method of the traditional Chinese medicine composition for treating the non-infectious diarrhea of the caged chicken further comprises the steps of extracting astragalus polysaccharides and extracting tangerine peel flavone;
the extraction method of the astragalus polysaccharide comprises the following steps: drying and crushing astragalus membranaceus decoction pieces, sieving by a 40-mesh sieve, taking 10g of astragalus membranaceus powder, adding pure water according to the designed liquid-material ratio, and performing ultrasonic extraction according to the designed corresponding extraction temperature and extraction time; filtering with gauze or absorbent cotton, concentrating to 20mL, adding 3 times volume of anhydrous ethanol, standing for several hours, and standing overnight in refrigerator for precipitation; centrifuging in a centrifuge and drying to obtain crude polysaccharide;
the extraction method of the tangerine peel flavone comprises the following steps: drying pericarpium Citri Tangerinae in a thermostat at 60 deg.C, cooling in a glass drier, pulverizing, drying, and sieving with 0.45mm sieve; weighing pericarpium Citri Tangerinae powder 3g, adding ethanol with certain concentration, extracting at different temperatures and material-solvent ratio for a period of time, vacuum filtering to obtain flavone crude solution, and concentrating by evaporation.
10. The traditional Chinese medicine compound granule prepared by the traditional Chinese medicine composition of claim 1, which is characterized by comprising the traditional Chinese medicine composition for treating non-infectious diarrhea of caged chickens, wherein the traditional Chinese medicine composition comprises, by mass, 10 parts of angelica polysaccharide, 15 parts of codonopsis pilosula polysaccharide, 5 parts of costunolide and dehydrocostuslactone mixture, 5 parts of green tangerine peel tannic acid, 5 parts of maltol, 5 parts of hawthorn total flavonoids, 5 parts of artemisinin, 5 parts of poria polysaccharide and 5 parts of licorice flavonoids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210808804.9A CN115381874B (en) | 2022-07-11 | 2022-07-11 | Traditional Chinese medicine composition and granule for treating chicken noninfectious diarrhea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210808804.9A CN115381874B (en) | 2022-07-11 | 2022-07-11 | Traditional Chinese medicine composition and granule for treating chicken noninfectious diarrhea and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115381874A true CN115381874A (en) | 2022-11-25 |
| CN115381874B CN115381874B (en) | 2024-02-20 |
Family
ID=84117454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210808804.9A Active CN115381874B (en) | 2022-07-11 | 2022-07-11 | Traditional Chinese medicine composition and granule for treating chicken noninfectious diarrhea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115381874B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251856A (en) * | 2013-05-08 | 2013-08-21 | 山西省肿瘤研究所 | Traditional Chinese medicine preparation for benefiting Qi and nourishing blood and preparation method of traditional Chinese medicine preparation |
| CN105194026A (en) * | 2015-10-09 | 2015-12-30 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine composition used for treating non-infectious diarrhea of cage rearing chicken as well as preparation method and application thereof |
| CN111558011A (en) * | 2020-06-15 | 2020-08-21 | 山西中医药大学 | Traditional Chinese veterinary medicine for preventing and treating chicken proventriculitis |
-
2022
- 2022-07-11 CN CN202210808804.9A patent/CN115381874B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251856A (en) * | 2013-05-08 | 2013-08-21 | 山西省肿瘤研究所 | Traditional Chinese medicine preparation for benefiting Qi and nourishing blood and preparation method of traditional Chinese medicine preparation |
| CN105194026A (en) * | 2015-10-09 | 2015-12-30 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine composition used for treating non-infectious diarrhea of cage rearing chicken as well as preparation method and application thereof |
| CN111558011A (en) * | 2020-06-15 | 2020-08-21 | 山西中医药大学 | Traditional Chinese veterinary medicine for preventing and treating chicken proventriculitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115381874B (en) | 2024-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103340334B (en) | Freshwater fish feed and preparation method thereof | |
| CN102178100B (en) | Low-tryptophan feed for hybrid chicken and preparation method of the low-tryptophan feed | |
| CN104472913A (en) | Application of Chinese medicinal herb layer feed additive | |
| CN104431498A (en) | Chinese herbal medicine laying hen feed additive and preparation method thereof | |
| CN112535239B (en) | Compound Chinese herbal medicine feed additive for daily health care and growth promotion of livestock and preparation and application thereof | |
| CN102462766A (en) | Chinese medicine powder formulation for treating cyanomycosis of laying hens | |
| CN115969909B (en) | Traditional Chinese medicine composition and fermented traditional Chinese medicine preparation for improving sub-health of sow as well as preparation method and application of traditional Chinese medicine composition and fermented traditional Chinese medicine preparation | |
| CN115381874B (en) | Traditional Chinese medicine composition and granule for treating chicken noninfectious diarrhea and preparation method thereof | |
| CN104431359A (en) | Rearing method of laying hens | |
| CN107691301A (en) | A kind of method of fish fast-growth | |
| CN112544812A (en) | Mixed-strain fermentation type Chinese herbal medicine additive for laying hens in later period of laying, and preparation method and application thereof | |
| CN111700927A (en) | Medicinal and edible composition with blood sugar reducing effect and preparation method and application thereof | |
| CN111084878A (en) | Biological medicine and medical total nutrient food for lung and respiratory system diseases and preparation method thereof | |
| CN110663954A (en) | Health food for eliminating dampness and expelling toxin and preparation method thereof | |
| CN109833402B (en) | Paeonia lactiflora pall anti-inflammatory liver-protecting wine and preparation method thereof | |
| CN104208168B (en) | A kind of for compound traditional Chinese medicine composite treating poultry respiratory infection and preparation method thereof | |
| CN113893316B (en) | Application of traditional Chinese medicine composition in preparation of medicine for improving chronic fatigue symptoms of people with damp heat mass | |
| CN108783443A (en) | A kind of tablet and preparation method thereof for internal organs conditioning | |
| CN102793869A (en) | Traditional Chinese medicine composition for controlling porcine viral diseases and preparation method thereof | |
| CN114949114B (en) | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof | |
| CN106900910A (en) | A kind of protect liver Se rich tea and preparation method thereof | |
| CN106727926B (en) | Medicine for resisting hepatic fibrosis and treating liver cirrhosis and preparation method thereof | |
| CN116808102A (en) | A fermented preparation for resisting stress and its preparation method | |
| CN105381336A (en) | Biological agent containing papaya extract and application thereof | |
| CN105055806A (en) | Medicinal preparation for treating diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |